- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02535962
Probiotics and Corticosteroids for Treating Periodic Fever, Aphthous Stomatitis, Pharyngitis, Cervical Adenitis (PFAPA) (PFAPA)
Effects of Probiotic Addition to Corticosteroid Treatment for PFAPA
Study Overview
Status
Intervention / Treatment
Detailed Description
Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) was first described in 1987 in a study of 12 pediatric patients. PFAPA is predominately considered a pediatric illness with onset typically occurring under the age of 5. This syndrome is characterized by periodic febrile episodes (39°C - 42°C) lasting an average of 4 days with recurrence approximately every 21-30 days. Patients classically exhibit at least one of three major associated symptoms; aphthous stomatitis, pharyngitis, or cervical adenitis. Between periods of fever, patients are asymptomatic and do not experience long-term deleterious effects on growth or development. Currently, the etiology of this syndrome is unknown but does not appear to be heritable or target specific populations.
Due to a lack of applicable diagnostic tests, the identification of PFAPA is predominantly dependent on patient history and physical examination. This methodology relies heavily upon clinical presentation of the patient's illness to rule out other causes of periodic fever. As a result of the unknown cause of PFAPA, there are several proposed treatment approaches available. Corticosteroids are the current standard of care; typically a single dose of prednisolone (1 mg/kg), given upon first signs of fever with a subsequent dose during the febrile period if necessary. Several studies have shown that administration of prednisolone was sufficient to abort the febrile episode. However, this treatment method typically results in a decrease in the healthy interval between fever reoccurrence. The reduction in fever allows for children to attend school and participate in other activates, but the increased frequency provides additional complications for children and parents.
Oral cimetidine, a histamine H-2 receptor agonist that results in reduced production of stomach acid, has also been used as possible treatment. This treatment has shown to inhibit febrile episodes, it was only effective in <30% of patients.
If medication therapy fails to resolve recurrent febrile episodes, the option of tonsillectomy presents a possible alternative. PFAPA syndrome was shown to resolve in the majority of patients, however this not preferred as a first line treatment due to the risks associated with surgery and general anesthesia.
Recently published literature suggests a potential new treatment for PFAPA targeting chemokines and proinflammatory cytokines. A possible method for the inhibition of cyclic inflammatory responses in PFAPA would be the exposure of patients to a safe level of continuous low-grade inflammation, resulting from an immune response. In previous studies investigating allergy and eczema relief in pediatric populations, it was shown that administration of probiotics induced elevated levels of inflammatory markers. These low level inflammatory responses resulted in no adverse effects and provided an immunologic activation benefit. Use of probiotics provides a previously unstudied approach to the treatment of PFAPA. Dr. Nicholas Bennett has also observed anecdotal evidence that patients who self-administered probiotics experienced relief of their PFAPA symptoms.
This is a randomized, prospective, double-blind, placebo-controlled study with the randomization being done by the research pharmacist using an equal randomization process, no stratification of patients. Dr. Bennett and other patient recruiters will remain blinded to the participant group assignment. The standard of care consists of corticosteroid dosing of 1 mg/kg of body weight given once at the onset of the febrile period, repeated once within 24 hours if necessary, but no more than two doses per cycle. The second dose of corticosteroid is only to be given within one day following the initial dosage if the fever persists. The investigational product will be administered daily for the duration of the study. For the investigational product patients will be instructed to take daily one sachet of the study product mixed into a 60 ml of water that is not hot. On days 90±7, 180±7 and 270±7 patients will come to the study site for re-supply of the probiotic and for evaluation of compliance. Throughout the 1-year followup period, parents will be asked to keep a journal to track corticosteroid usage, probiotic usage, additional medication usage, fever intensity, and associated symptoms. Standardized thermometers will be provided to ensure consistency. These journals will be collected and patient progress will be monitored at the standard care visits every three months. In addition, follow-up phone calls will be made monthly to assess progress and to address any concerns.
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- diagnosis or confirmation of diagnosis of PFAPA from Dr. Bennett based on clinical or laboratory data
- is or will be undergoing treatment for PFAPA at CCMC
- agrees to the consent and, if necessary, assent forms
- is between 1 and 12 years of age
Exclusion Criteria:
- is currently taking another probiotic regularly (>=2 times/ week)
- is allergic to ingredients in the probiotic or placebo
- may react adversely to the probiotic due to any form of immune deficiency or chronic disease including pulmonary, renal, cardiac disorders including underlying structural heart disease, gastrointestinal disease, or diabetes
- is not a proficient English speaker
- does not agree to the consent and/or assent forms
- patients who use antibiotics or have used them within a month of the study start
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Corticosteriod + Probiotic Treatment
Corticosteroid dosing of 1 mg/kg of body weight given once at the onset of the febrile period, repeated once within 24 hours if necessary, but no more than two doses per cycle. The second dose of corticosteroid treatment is only to be given within one day following the initial dosage if the fever persists. Investigational drug (Intervention is Lactobacillus acidophilus and Bifidobacterium lactis): Patients will be instructed to take one sachet of the study product mixed into a 60 ml of water that is not hot. Each sachet will contain Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 at a dose of 5*109 CFU of each strain. The investigational product will be taken daily for the duration of the study, which is a year. |
study product will be freeze dried and put into foil sachets
Other Names:
|
Placebo Comparator: Corticosteriod + PlaceboTreatment
Corticosteroid dosing of 1 mg/kg of body weight given once at the onset of the febrile period, repeated once within 24 hours if necessary, but no more than two doses per cycle. The second dose of corticosteroid treatment is only to be given within one day following the initial dosage if the fever persists. Placebo: will be taken daily and patients will be instructed to take one sachet of placebo mix into 60ml of water that is not to hot. The placebo will be taken daily for the duration of the study, which is one year. Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product. |
Placebo will look and taste like the investigational product.
This also will be provided in a foil sachets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effects of the investigational treatment
Time Frame: Time to event: number of fever-free days will be calculated, as well as the average number of days between fever cycles from baseline to end of study which is 12 months.
|
Increased healthy intervals between cyclic febrile episodes in patients with PFAPA compared to patients being solely treated with corticosteroids.
|
Time to event: number of fever-free days will be calculated, as well as the average number of days between fever cycles from baseline to end of study which is 12 months.
|
Safety of the investigational treatment - reported descriptively as percentages of patients experiencing adverse and serious adverse events.
Time Frame: Time to event: number of fever-free days will be calculated, as well as the average number of days between fever cycles from baseline to end of study which is 12 months.
|
Safety will be reported descriptively as percentages of patients experiencing adverse and serious adverse events.
|
Time to event: number of fever-free days will be calculated, as well as the average number of days between fever cycles from baseline to end of study which is 12 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximal fever experienced during a PFAPA febrile episode will be recorded as an average of the peak temperature recorded during each episode throughout the year and compared between the study groups
Time Frame: Maximal fever experienced during a PFAPA febrile episode will be recorded as an average of the peak temperature recorded during each episode throughout the year
|
Decreased maximal fever experienced during a PFAPA febrile episode.
|
Maximal fever experienced during a PFAPA febrile episode will be recorded as an average of the peak temperature recorded during each episode throughout the year
|
Number of administrations of corticosteroid necessary for treatment of PFAPA syndrome, recorded as the average number of administrations per fever episode throughout the year
Time Frame: Number of administrations of corticosteroid necessary for treatment of PFAPA syndrome, recorded as the average number of administrations per fever episode throughout the year
|
Decreased administrations of corticosteroid necessary for treatment of PFAPA syndrome.
|
Number of administrations of corticosteroid necessary for treatment of PFAPA syndrome, recorded as the average number of administrations per fever episode throughout the year
|
The average duration of the individual cyclic febrile episodes
Time Frame: average duration of the individual cyclic febrile episodes in patients with PFAPA will be assessed from baseline to the end of study which is 1 year
|
Decrease duration of the individual cyclic febrile episodes in patients with PFAPA.
|
average duration of the individual cyclic febrile episodes in patients with PFAPA will be assessed from baseline to the end of study which is 1 year
|
The number of patients undergoing tonsillectomy will be compared between the study groups
Time Frame: At any time during the study from baseline to end of study, which is 12 months this will recorded
|
Fewer patients undergoing tonsillectomy as a treatment for PFAPA syndrome
|
At any time during the study from baseline to end of study, which is 12 months this will recorded
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Nicholas Bennett, MBBChir PhD, Connecticut Children's Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lymphatic Diseases
- Genetic Diseases, Inborn
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Mouth Diseases
- Hereditary Autoinflammatory Diseases
- Body Temperature Changes
- Fever
- Stomatitis
- Pharyngitis
- Stomatitis, Aphthous
- Familial Mediterranean Fever
- Lymphadenitis
Other Study ID Numbers
- 15-017
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pharyngitis
-
Vastra Gotaland RegionGöteborg University; James Cook University, Queensland, AustraliaCompletedTonsillitis | Pharyngitis | Sore Throat | Streptococcus Pharyngitis | Pharyngitis BacterialSweden
-
Andrew SteerNational Health and Medical Research Council, Australia; Queen Fabiola Children... and other collaboratorsCompletedBacterial Infections | Gram-Positive Bacterial Infections | Strep Throat | Streptococcus Pharyngitis | Streptococcus Pyogenes Pharyngitis | Streptococcus Pyogenes Infection | Group A Streptococcus: B Hemolytic Pharyngitis | Group A Streptococcal InfectionAustralia
-
Luminex CorporationCompletedPharyngitis BacterialUnited States
-
Hamilton Health Sciences CorporationRecruiting
-
University of Wisconsin, MadisonNational Institute of Allergy and Infectious Diseases (NIAID)Recruiting
-
Oman Medical Speciality BoardCompleted
-
Megainpharm GmbHTerminated
-
Dentaid SLMethodexRecruiting
-
Northwell HealthIcahn School of Medicine at Mount Sinai; Agency for Healthcare Research and...CompletedPneumonia | Strep PharyngitisUnited States
-
Dalin Tzu Chi General HospitalRecruitingChronic PharyngitisTaiwan
Clinical Trials on Lactobacillus acidophilus and Bifidobacterium lactis
-
DaniscoCompleted
-
University of CopenhagenCompleted
-
Faculty of Medical Sciences, Clinical HospitalCompleted
-
University of Wisconsin, MadisonNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedClostridium DifficileUnited States
-
Hvidovre University HospitalChr HansenTerminated
-
Universidad de AlmeriaCompleted
-
National Health Service, United KingdomFerring Pharmaceuticals; Hull University Teaching Hospitals NHS Trust; North... and other collaboratorsCompleted
-
Fonterra Research CentreSprim Advanced Life Sciences; Xinhua Hospital, Shanghai Jiao Tong University...CompletedEffect of Probiotics on Infections in Infants.China